With safety concerns being the major cause for failures in phases 1/2 clinical trials, it’s essential to develop more predictive models within preclinical drug discovery to improve data translatability.
In this webinar, CN Bio Senior Scientist Dr. Ovidiu Novac will discuss how a human liver microphysiological system (MPS), or Liver-on-a-chip, can be used to understand the causality and mechanistic aspects of drug-induced liver injury (DILI).
Ovidiu will discuss how his team validated the MPS using a broad set of mild to severely hepatotoxic compounds and how the MPS delivered novel insights not previously seen in vitro.
- Discover how the liver MPS can be used to detect mild through to severe DILI toxicants
- Understand how MPS can be used to generate mechanistic signatures of hepatotoxicity
- Enable your scientists to reduce drug attrition in the early phases of clinical trials